Afenyi-Annan A, Kail M, Combs MR, et al. Lack of Duffy antigen expression is associated with organ damage in patients with sickle cell disease. Transfusion. 2008;48:917-924.
Ataka, KI, Smith WR, DeCastro LM, et al. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood: 2008;11(8):3991-3997.
Ballas, S.K., Sickle Cell Anaemia: Progress in Pathogenesis and Treatment. Drugs 2002: 62(8); 1143-1172.
Bianchi N, Zuccato C, Lampronti I, et al. Fetal hemoglobin inducers from the natural world: a novel approach for the identification of drugs for the treatment of B-thalassemia and Sickle-cell anemia. eCAM: 2009; 6(2)141-151.
Centers for Disease Control and Prevention. Sickle cell disease (SCD). Available at: http://www.cdc.gov/ncbddd/sicklecell/index.html. Accessed February 17, 2016.
Harmening DM, Clinical Hematology and Fundementals of Hemostatis. 5th ed. Philadelphia, PA: F.A. Davis; 2008.
Inati A, Koussa S. Taher A, Perrine, S. Sickle cell disease: New insights into pathophysiology and treatment. Pediatr Ann. 2008:37(5).
Kaushansky K, Lichtman MA, Prchal JT, et al. Williams Hematology 9th ed. McGraw Hill; 2015.
Niscola P, Sorrentino F, Scaramucci, L, et al. Pain syndromes in Sickle Cell Disease: An update. American Academy of Pain Medicine. 2009:10(3):470-480.
Yoon SL, Black S. Comprehensive, integrative management of pain for patients with Sickle-Cell Disease. Journal of Alternative and Complementary Medicine. 2006: 12(10); 995-1001.